Research ExplorerPublicationsEfficacy of vemurafenib in a trametinib-resistant stage IV m...

Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter

Standard

Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. / Bernhardt, Mathias; Orouji, Elias; Larribere, Lionel; Gebhardt, Christoffer; Utikal, Jochen.

In: CLIN CANCER RES, Vol. 20, No. 9, 01.05.2014, p. 2498-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bernhardt, M, Orouji, E, Larribere, L, Gebhardt, C & Utikal, J 2014, 'Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter', CLIN CANCER RES, vol. 20, no. 9, pp. 2498-9. https://doi.org/10.1158/1078-0432.CCR-13-2349

APA

Bernhardt, M., Orouji, E., Larribere, L., Gebhardt, C., & Utikal, J. (2014). Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. CLIN CANCER RES, 20(9), 2498-9. https://doi.org/10.1158/1078-0432.CCR-13-2349

Vancouver

Bernhardt M, Orouji E, Larribere L, Gebhardt C, Utikal J. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. CLIN CANCER RES. 2014 May 1;20(9):2498-9. https://doi.org/10.1158/1078-0432.CCR-13-2349

Bibtex

@article{52e463243d554610a99e0e0cbfe1f485,
title = "Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter",
keywords = "Adult, Antineoplastic Agents/pharmacology, Drug Resistance, Neoplasm, Fatal Outcome, Humans, Indoles/pharmacology, Male, Melanoma/drug therapy, Neoplasm Staging, Protein Kinase Inhibitors/pharmacology, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Pyridones/pharmacology, Pyrimidinones/pharmacology, Sulfonamides/pharmacology, Treatment Outcome, Vemurafenib",
author = "Mathias Bernhardt and Elias Orouji and Lionel Larribere and Christoffer Gebhardt and Jochen Utikal",
year = "2014",
month = may,
day = "1",
doi = "10.1158/1078-0432.CCR-13-2349",
language = "English",
volume = "20",
pages = "2498--9",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter

AU - Bernhardt, Mathias

AU - Orouji, Elias

AU - Larribere, Lionel

AU - Gebhardt, Christoffer

AU - Utikal, Jochen

PY - 2014/5/1

Y1 - 2014/5/1

KW - Adult

KW - Antineoplastic Agents/pharmacology

KW - Drug Resistance, Neoplasm

KW - Fatal Outcome

KW - Humans

KW - Indoles/pharmacology

KW - Male

KW - Melanoma/drug therapy

KW - Neoplasm Staging

KW - Protein Kinase Inhibitors/pharmacology

KW - Proto-Oncogene Proteins B-raf/antagonists & inhibitors

KW - Pyridones/pharmacology

KW - Pyrimidinones/pharmacology

KW - Sulfonamides/pharmacology

KW - Treatment Outcome

KW - Vemurafenib

U2 - 10.1158/1078-0432.CCR-13-2349

DO - 10.1158/1078-0432.CCR-13-2349

M3 - SCORING: Journal article

C2 - 24789037

VL - 20

SP - 2498

EP - 2499

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 9

ER -